Aveanna's Heartways Program Receives CHAP Disease Program Certification
MWN-AI** Summary
Aveanna Healthcare has achieved significant recognition with the awarding of its Heartways program the Disease Program Certification for Heart Failure by the Community Health Accreditation Partner (CHAP). This certification, announced on February 11, 2026, underscores Aveanna's adherence to rigorous industry standards for quality in home and community-based healthcare. CHAP, an independent accrediting body, evaluates programs on criteria such as structure, quality metrics, clinician education, and patient self-management tools.
Nathan DeGodt, CHAP's President & CEO, commended Aveanna’s commitment to delivering consistent, evidence-based care that enhances clinical performance. This achievement is particularly noteworthy given Aveanna’s extensive reach in caring for patients and families. The Heartways program, which is scientifically validated, has demonstrated improved patient outcomes by offering comprehensive education, daily routine management, and symptom monitoring to detect early warning signs for heart disease.
Furthermore, for hospice patients, Heartways provides palliative care protocols, focusing on symptom management to ensure greater comfort for patients and their families. Heart disease remains a leading chronic condition in the United States, significantly impacting healthcare costs. Therefore, the Heartways program not only aims to improve the quality of life for patients but also seeks to reduce avoidable hospital readmissions.
Shane Brinkerhoff, President of Aveanna's Home Health and Hospice Division, emphasized that the program is integral to their mission of innovation and quality care. With locations across 38 states and services designed to promote lower-cost alternatives to hospitalization, Aveanna is positioned to redefine the standards of care for individuals living with heart disease. For more information about Aveanna Healthcare and the Heartways program, interested parties can visit their respective websites.
MWN-AI** Analysis
The recent awarding of the Disease Program Certification for Heart Failure to Aveanna Healthcare's Heartways program by the Community Health Accreditation Partner (CHAP) marks a significant milestone for the company. This recognition underscores Aveanna's commitment to delivering high-quality, evidence-based care, particularly within the home health and hospice sectors of the increasingly vital healthcare landscape.
Investors should view this certification as a strategic advantage for Aveanna, given that heart disease remains a leading cause of healthcare expenditures in the U.S. Consequently, the Heartways program not only enhances patient outcomes but also positions Aveanna as a key player in mitigating hospital readmissions, which is a critical metric for both patient care and healthcare cost management.
The CHAP certification strengthens Aveanna's competitive edge by signaling to potential patients and partners that their programs adhere to rigorous standards. In a market where healthcare providers are frequently scrutinized for quality, Aveanna's validation from an esteemed accrediting body could bolster its reputation, potentially driving patient volume and revenue growth.
Furthermore, the Heartways program directly addresses the rising demand for home healthcare solutions in a post-pandemic world, capitalizing on the increasing preference for in-home care among patients with chronic conditions. As regulatory pressures mount on healthcare providers to improve care quality while controlling costs, Aveanna's focus on innovative, patient-centric programs aligns well with the overall industry trajectory towards value-based care.
In summary, Aveanna's Heartways program certification is a catalyst for growth, reinforcing its branding, expanding market reach, and enhancing its value proposition. As healthcare paradigms shift further towards home and community-based models, Aveanna Healthcare stands well-positioned for future market success, making it an attractive option for investors seeking exposure in the resilient home healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ATLANTA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Community Health Accreditation Partner (CHAP), an independent, non-profit accrediting body for home and community-based healthcare, and Aveanna Healthcare (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care in the home, announced today that Aveanna Home Health and Hospice, a division of Aveanna Healthcare, has been awarded a Disease Program Certification for Heart Failure under the CHAP Disease Program Standards.
CHAP certification demonstrates that Aveanna Home Health and Hospice meets the industry’s highest nationally recognized standards. CHAP’s rigorous program evaluation focuses on program structure and function, quality metrics, advanced education for clinicians, and demonstrated self-management tools for patients.
“By achieving CHAP Disease Program Certification, Aveanna Home Health and Hospice has shown a commitment to excellence,” said Nathan DeGodt, CHAP President & CEO. “Their efforts to strengthen their clinical performance using evidence-based protocols means consistency becomes a result, not a goal.
“Achieving CHAP’s Enterprise Disease Program Certification for Heart Failure is a significant accomplishment, especially for an organization serving patients and families at Aveanna’s scale. This recognition reflects Aveanna’s commitment to evidence-based care, strong clinical education, and consistent disease management practices that help reduce hospitalizations and strengthen patient self-management,” added DeGodt. “Their Heartways program demonstrates how a thoughtful, well-structured framework can improve outcomes across diverse communities. We’re proud to partner with Aveanna as they continue advancing high-quality care for individuals living with heart failure.”
Aveanna’s Heartways is a scientifically validated care program that leads to improved outcomes for home health patients with heart disease. For Home Health patients, Heartways leads to improved outcomes by providing comprehensive patient education, guidance on daily routines, and monitoring symptoms to catch early warning signs, among other aspects. For hospice patients, the program offers palliative-focused protocols, including improved symptom management with tools that help caregivers recognize changes and provide compassionate support for the patient’s family.
Heart disease remains one of the leading chronic diseases in this country and one of the costliest to the nation’s healthcare system. According to the American Heart Association, between 2017 and 2020, 127.9 million U.S. adults (48.6%) had some form of cardiovascular disease, leading to direct and indirect costs of $422.3 billion.
“The Heartways program represents our commitment to quality, value, and innovation. This program delivers better outcomes for home health patients and greater comfort for our hospice patients,” said Shane Brinkerhoff, President of Home Health and Hospice at Aveanna Healthcare. “This program will improve the lives of home health patients with heart disease while reducing avoidable readmissions for our hospital partners. In addition, patients with end-stage heart disease will be able to experience a higher quality of life through our hospice care. We are proud to introduce this program to our patients and partners, and we are excited to work with CHAP as we help to redefine the national standards of quality care.”
About Aveanna Healthcare
Headquartered in Atlanta, Georgia, Aveanna Healthcare is one of the nation’s leading providers of home care, with locations in 38 states providing a broad range of pediatric and adult healthcare. Aveanna’s Home Health and Hospice Division provides a variety of services to patients and their families across 15 states. Aveanna’s services are designed to provide a high-quality, lower-cost alternative to prolonged hospitalization. For more information about Aveanna Healthcare, please contact communications@aveanna.com or visit https://www.aveanna.com. To learn more about the Heartways program, visit https://www.aveanna.com/heartways.
About Community Health Accreditation Partner, Inc. (CHAP)
CHAP is an independent, not-for-profit accrediting body for community-based healthcare organizations. Created in 1965, CHAP was the first to recognize the need and value for accreditation in community-based care. CHAP is the oldest national, community-based accrediting body, with more than 9,000 agencies currently accredited nationwide. Through “deeming authority” granted by the Centers for Medicare and Medicaid Services (CMS), CHAP has the regulatory authority to survey agencies providing home health, hospice, and home medical equipment services to determine if they meet the Medicare Conditions of Participation and CMS Quality Standards. CHAP’s purpose is to define and advance the highest standards of community-based care.
For more information about the CHAP Disease Program Certification, please visit the CHAP Learning Solutions website at https://chapinc.org/services/disease-program-certification/.
Media Contact
Aveanna Healthcare
CHAP
619-800-7255
education@chapinc.org
FAQ**
How will Aveanna Healthcare Holdings Inc. (AVAH) leverage its CHAP Disease Program Certification for Heart Failure to enhance its market position in home health and hospice services?
What specific clinical outcomes and cost savings does Aveanna Healthcare Holdings Inc. (AVAH) aim to demonstrate through its Heartways program after achieving CHAP certification?
How does the CHAP certification impact Aveanna Healthcare Holdings Inc. (AVAH) in its partnerships with hospitals and other healthcare providers?
Given the rise in cardiovascular disease, how does Aveanna Healthcare Holdings Inc. (AVAH) plan to expand its reach and services in response to the growing demand for heart failure management?
**MWN-AI FAQ is based on asking OpenAI questions about Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH).
NASDAQ: AVAH
AVAH Trading
-1.58% G/L:
$7.15 Last:
260,713 Volume:
$7.22 Open:
